Zacks: Analysts Anticipate CymaBay Therapeutics Inc (CBAY) Will Announce Earnings of -$0.12 Per Share

Wall Street analysts forecast that CymaBay Therapeutics Inc (NASDAQ:CBAY) will announce ($0.12) earnings per share for the current quarter, Zacks reports. Two analysts have issued estimates for CymaBay Therapeutics’ earnings. The highest EPS estimate is $0.03 and the lowest is ($0.22). CymaBay Therapeutics reported earnings of ($0.30) per share during the same quarter last year, which would suggest a positive year-over-year growth rate of 60%. The firm is expected to announce its next quarterly earnings report on Thursday, March 22nd.

On average, analysts expect that CymaBay Therapeutics will report full year earnings of ($0.82) per share for the current fiscal year, with EPS estimates ranging from ($0.93) to ($0.62). For the next fiscal year, analysts anticipate that the company will report earnings of ($0.90) per share, with EPS estimates ranging from ($1.02) to ($0.82). Zacks Investment Research’s EPS averages are an average based on a survey of sell-side research analysts that follow CymaBay Therapeutics.

CymaBay Therapeutics (NASDAQ:CBAY) last announced its quarterly earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.21) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.19) by ($0.02). During the same quarter in the prior year, the company posted ($0.25) earnings per share.

A number of research analysts have recently commented on CBAY shares. Cantor Fitzgerald reiterated a “buy” rating and issued a $16.00 price target on shares of CymaBay Therapeutics in a research note on Tuesday, September 26th. Piper Jaffray Companies reiterated a “buy” rating and issued a $12.00 price target on shares of CymaBay Therapeutics in a research note on Friday, October 27th. Oppenheimer set a $15.00 price target on CymaBay Therapeutics and gave the company a “buy” rating in a research note on Monday, October 30th. HC Wainwright reiterated a “buy” rating and issued a $12.00 price target on shares of CymaBay Therapeutics in a research note on Tuesday, November 28th. Finally, Leerink Swann reiterated a “buy” rating and issued a $16.00 price target on shares of CymaBay Therapeutics in a research note on Tuesday, November 28th. One research analyst has rated the stock with a sell rating, one has given a hold rating and ten have issued a buy rating to the company. The stock presently has an average rating of “Buy” and an average target price of $14.50.

In related news, Director Kurt Von Emster sold 59,209 shares of the firm’s stock in a transaction on Tuesday, October 31st. The stock was sold at an average price of $9.27, for a total transaction of $548,867.43. Following the completion of the transaction, the director now directly owns 90,000 shares of the company’s stock, valued at approximately $834,300. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Carl Goldfischer sold 18,000 shares of the firm’s stock in a transaction on Thursday, November 2nd. The stock was sold at an average price of $8.66, for a total value of $155,880.00. Following the transaction, the director now directly owns 9,000 shares of the company’s stock, valued at $77,940. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 304,749 shares of company stock valued at $2,841,832. 15.10% of the stock is owned by corporate insiders.

Several hedge funds have recently bought and sold shares of CBAY. Perceptive Advisors LLC bought a new position in shares of CymaBay Therapeutics in the 3rd quarter worth about $18,948,000. Citadel Advisors LLC bought a new position in shares of CymaBay Therapeutics in the 3rd quarter worth about $5,159,000. EAM Investors LLC bought a new position in shares of CymaBay Therapeutics in the 3rd quarter worth about $4,788,000. Omega Fund Management LLC raised its position in shares of CymaBay Therapeutics by 82.9% in the 3rd quarter. Omega Fund Management LLC now owns 551,477 shares of the biopharmaceutical company’s stock worth $4,445,000 after acquiring an additional 250,000 shares in the last quarter. Finally, Ameriprise Financial Inc. bought a new position in shares of CymaBay Therapeutics in the 3rd quarter worth about $1,536,000. 69.12% of the stock is owned by hedge funds and other institutional investors.

Shares of CymaBay Therapeutics (NASDAQ CBAY) traded up $0.06 on Friday, hitting $10.20. The stock had a trading volume of 612,884 shares, compared to its average volume of 543,697. CymaBay Therapeutics has a one year low of $1.46 and a one year high of $10.50. The company has a market cap of $450.06, a PE ratio of -10.10 and a beta of 1.82. The company has a quick ratio of 7.39, a current ratio of 7.39 and a debt-to-equity ratio of 0.04.

WARNING: This report was originally reported by American Banking News and is the property of of American Banking News. If you are reading this report on another publication, it was illegally stolen and republished in violation of U.S. & international copyright legislation. The original version of this report can be read at https://www.americanbankingnews.com/2018/01/20/zacks-analysts-anticipate-cymabay-therapeutics-inc-cbay-will-announce-earnings-of-0-12-per-share.html.

About CymaBay Therapeutics

CymaBay Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies to treat metabolic diseases, including serious rare and orphan diseases. The Company’s product candidates include Arhalofenate, MBX-8025 and MBX-2982. Arhalofenate is used to treat gout.

Get a free copy of the Zacks research report on CymaBay Therapeutics (CBAY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for CymaBay Therapeutics (NASDAQ:CBAY)

Receive News & Ratings for CymaBay Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CymaBay Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply